Infectious Disease

This week's focused analysis examines a phase 1b trial of SER-155, a cultivated multi-strain bacterial oral live biotherapeutic product (LBP), in allogeneic hematopoietic cell transplantation (HCT) recipients—a population facing exceptionally high risk for bloodstream infections (BSIs), occurring in 20–40% of allogeneic HCT recipients depending on risk stratification and remaining a leading cause of post-transplantation morbidity and mortality. Trial design included both randomized-controlled and open-label cohorts. In the randomized cohort, SER-155 demonstrated safety comparable to placebo while showing numerically reduced BSI incidence; however, the phase 1b design limits statistical power and precludes definitive efficacy claims. The mechanism likely involves restoration of protective commensal bacteria depleted during intensive conditioning and antimicrobial prophylaxis, thereby reducing translocation of pathogenic organisms and supporting intestinal barrier integrity. For ID physicians managing immunocompromised hosts, this represents a non-antimicrobial stewardship opportunity—using directed bacterial therapy as infection prevention rather than escalating broad-spectrum coverage, particularly relevant as carbapenem-resistant organisms proliferate. The trial represents exploratory-stage evidence; external multi-center validation and phase 2/3 trials with pre-specified efficacy endpoints are required before clinical adoption. Phase 1b design indicates a 2–3 year pathway to phase 2/3 trials; no FDA approval timeline has been announced as of publication. Critical limitations: durability of benefit beyond the trial period remains unknown, manufacturing scalability and cost-effectiveness have not been established, microbiota recovery kinetics post-SER-155 administration require further characterization, and it remains unclear whether benefit persists when SER-155 is combined with standard antimicrobial prophylaxis regimens (fluoroquinolone, azole) commonly administered to HCT recipients.